Impact of Pulmonary Hypertension Hemodynamic Phenotype on Incident Atrial Fibrillation.


Journal

Cardiology
ISSN: 1421-9751
Titre abrégé: Cardiology
Pays: Switzerland
ID NLM: 1266406

Informations de publication

Date de publication:
2023
Historique:
received: 12 04 2023
accepted: 25 05 2023
medline: 22 8 2023
pubmed: 6 6 2023
entrez: 5 6 2023
Statut: ppublish

Résumé

Atrial fibrillation/flutter (AF) is common among patients with pulmonary hypertension (PH) and is associated with poor clinical outcomes. AF has been shown to occur more commonly among patients with postcapillary PH, although AF also occurs among patients with precapillary PH. The goal of this study was to evaluate the independent impact of PH hemodynamic phenotype on incident AF among patients with PH. We retrospectively identified 262 consecutive patients, without a prior diagnosis of atrial arrhythmias, seen at the PH clinic at Mayo Clinic, Florida, between 1997 and 2017, who had right heart catheterization and echocardiography performed, with follow-up for outcomes through 2021. Kaplan-Meier analysis and Cox-proportional hazards regression modeling were used to evaluate the independent effect of PH hemodynamic phenotype on incident AF. Our study population was classified into two broad PH hemodynamic groups: precapillary (64.9%) and postcapillary (35.1%). The median age was 59.5 years (Q1: 48.4, Q3: 68.4), and 72% were female. In crude models, postcapillary PH was significantly associated with incident AF (HR 2.17, 95% CI: 1.26-3.74, p = 0.005). This association was lost following multivariable adjustment, whereas left atrial volume index remained independently associated with incident AF (aHR 1.30, 95% CI: 1.09-1.54, p = 0.003). We found PH hemodynamic phenotype was not significantly associated with incident AF in our patient sample; however, echocardiographic evidence of left atrial remodeling appeared to have a greater impact on AF development. Larger studies are needed to validate these findings and identify potential modifiable risk factors for AF in this population.

Identifiants

pubmed: 37276844
pii: 000531402
doi: 10.1159/000531402
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

353-362

Informations de copyright

© 2023 S. Karger AG, Basel.

Auteurs

Andrea Carolina Morales-Lara (AC)

Department of Cardiovascular Medicine, Mayo Clinic, Jacksonville, Florida, USA.

Wiaam Elkhatib (W)

Department of Internal Medicine, Mayo Clinic, Jacksonville, Florida, USA.

Oludamilola Oluleye (O)

Essentia Health Heart and Vascular Center, Fargo, North Dakota, USA.

Rashid Alhusain (R)

Department of Cardiovascular Medicine, Mayo Clinic, Jacksonville, Florida, USA.

Amjad Saad (A)

Department of Cardiovascular Medicine, Mayo Clinic, Jacksonville, Florida, USA.

Najiyah Salwa (N)

Department of Cardiovascular Medicine, Mayo Clinic, Jacksonville, Florida, USA.

Habeeba Siddiqui (H)

Department of Quantitative Health Sciences, Mayo Clinic, Jacksonville, Florida, USA.

Mikolaj A Wieczorek (MA)

Department of Quantitative Health Sciences, Mayo Clinic, Jacksonville, Florida, USA.

Jordan Ray (J)

Department of Cardiovascular Medicine, Mayo Clinic, Jacksonville, Florida, USA.

Pragnesh Parikh (P)

Department of Cardiovascular Medicine, Mayo Clinic, Jacksonville, Florida, USA.

Charles Burger (C)

Department of Pulmonary Medicine, Mayo Clinic, Jacksonville, Florida, USA.

Brian Shapiro (B)

Department of Cardiovascular Medicine, Mayo Clinic, Jacksonville, Florida, USA.

Fred Kusumoto (F)

Department of Cardiovascular Medicine, Mayo Clinic, Jacksonville, Florida, USA.

Dilip Pillai (D)

Department of Cardiovascular Medicine, Mayo Clinic, Jacksonville, Florida, USA.

Demilade Adedinsewo (D)

Department of Cardiovascular Medicine, Mayo Clinic, Jacksonville, Florida, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH